Mass Drug Administration for Malaria: A Means to What end?

Ingrid Chen¹, Roly Gosling¹, Chris Drakeley², Teun Bousema^{2

3}

Affiliations

¹ Malaria Elimination Initiative, Global Health Group, University of California-San Francisco.
² Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom.
³ Department of Medical Microbiology, Radboud University Nijmegen Medical Center, The Netherlands.

Editorial

Ingrid Chen et al. J Infect Dis. 2016.

. 2016 Dec 15;214(12):1790-1792.

doi: 10.1093/infdis/jiw484.

Ingrid Chen¹, Roly Gosling¹, Chris Drakeley², Teun Bousema^{2

3}

¹ Malaria Elimination Initiative, Global Health Group, University of California-San Francisco.
² Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom.
³ Department of Medical Microbiology, Radboud University Nijmegen Medical Center, The Netherlands.

No abstract available

Keywords: Zambia; dihydroartemisinin-piperaquine; elimination; falciparum.

Comment on

Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial.
Eisele TP, Bennett A, Silumbe K, Finn TP, Chalwe V, Kamuliwo M, Hamainza B, Moonga H, Kooma E, Chizema Kawesha E, Yukich J, Keating J, Porter T, Conner RO, Earle D, Steketee RW, Miller JM. Eisele TP, et al. J Infect Dis. 2016 Dec 15;214(12):1831-1839. doi: 10.1093/infdis/jiw416. J Infect Dis. 2016. PMID: 27923947 Free PMC article. Clinical Trial.